Figure 2. ADAMTS9-AS2 expression is clearly downregulated in ccRCC tissues and cell lines. (A) ADAMTS9-AS2 showed decreased levels of expression in 76 clinical ccRCC tissues compared to those of the normal adjacent tissues, as analyzed by qRT-PCR. (B) ADAMTS9-AS2 displayed significantly decreased expression levels in three ccRCC cell lines (786-O, caki-1 and 769-P) compared to those of two normal renal proximal tubular epithelial cell lines (HKC, HK-2). (C) Kaplan-Meier analysis of the association between ADAMTS9-AS2 expression and the survival time in 76 clinical ccRCC patients. Three independent experiments were performed and data shown are mean ± SD. Statistically significant differences are indicated as *, P<0.05, **, P<0.01, ***, P<0.001; Student’s t-test. ADAMTS9-AS2, ADAM metallopeptidase with thrombospondin type 1 motif, 9 antisense RNA 2; ccRCC, clear cell renal cell carcinoma; qRT-PCR, quantitative real-time polymerase chain reaction; SD, standard deviation.